Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

Eitemau Tebyg

• Aromatase Inhibitors (AIs) Versus Not (Placebo/Observation) as Late Extended Adjuvant Therapy for Postmenopausal Women with Early Stage Breast Cancer (BC): Overviews of Randomized Trials of AIs after similar to 5 Years of Tamoxifen
  gan: Goss, P, et al.
  Cyhoeddwyd: (2009)
• Aromatase inhibitors versus tarnoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies
  gan: Ingle, J, et al.
  Cyhoeddwyd: (2009)
• Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
  gan: Tomoya Sawada, MD, et al.
  Cyhoeddwyd: (2023-06-01)
• Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: Beneficial effect of bisphosphonates
  gan: Pineda-Moncusí, M, et al.
  Cyhoeddwyd: (2019)
• Tamoxifen control arms in trials of aromatase inhibitors: possible influence on safety data
  gan: Sven Kurbel
  Cyhoeddwyd: (2008-08-01)